Literature DB >> 30571321

Discrepancy Between Pathological Progression and Clinical Stability in a Young Patient With Hypertrophic Cardiomyopathy.

Betty Raman1, David Wen1, Kenneth Chan1, Hugh Watkins1, Stefan Neubauer1, Masliza Mahmod1.   

Abstract

Entities:  

Keywords:  cardiology; fibrosis; gadolinium; natural history; strain

Mesh：

Year:  2018        PMID： 30571321      PMCID： PMC6310048          DOI： 10.1161/CIRCIMAGING.118.008154

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN： 1941-9651            Impact factor:   7.792


× No keyword cloud information.
  6 in total

1.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  Circulation       Date:  2011-11-08       Impact factor: 29.690

2.  Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy.

Authors:  Anna Axelsson Raja; Hoshang Farhad; Anne Marie Valente; John-Paul Couce; John Lynn Jefferies; Henning Bundgaard; Kenneth Zahka; Harry Lever; Anne M Murphy; Euan Ashley; Sharlene M Day; Mark V Sherrid; Ling Shi; David A Bluemke; Charles E Canter; Steven D Colan; Carolyn Y Ho
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

3.  Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy.

Authors:  Hong-Mi Choi; Kyung-Hee Kim; Joo Myung Lee; Yeonyee E Yoon; Seung-Pyo Lee; Eun-Ah Park; Whal Lee; Yong-Jin Kim; Goo-Yeong Cho; Dae-Won Sohn; Hyung-Kwan Kim
Journal:  Heart       Date:  2015-04-20       Impact factor: 5.994

4.  Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy.

Authors:  Giancarlo Todiere; Giovanni Donato Aquaro; Paolo Piaggi; Francesco Formisano; Andrea Barison; Pier Giorgio Masci; Elisabetta Strata; Lorenzo Bacigalupo; Mario Marzilli; Alessandro Pingitore; Massimo Lombardi
Journal:  J Am Coll Cardiol       Date:  2012-09-04       Impact factor: 24.094

5.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Authors:  Perry M Elliott; Aris Anastasakis; Michael A Borger; Martin Borggrefe; Franco Cecchi; Philippe Charron; Albert Alain Hagege; Antoine Lafont; Giuseppe Limongelli; Heiko Mahrholdt; William J McKenna; Jens Mogensen; Petros Nihoyannopoulos; Stefano Nistri; Petronella G Pieper; Burkert Pieske; Claudio Rapezzi; Frans H Rutten; Christoph Tillmanns; Hugh Watkins
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

6.  Hypertrophic Cardiomyopathy Registry: The rationale and design of an international, observational study of hypertrophic cardiomyopathy.

Authors:  Christopher M Kramer; Evan Appelbaum; Milind Y Desai; Patrice Desvigne-Nickens; John P DiMarco; Matthias G Friedrich; Nancy Geller; Sarahfaye Heckler; Carolyn Y Ho; Michael Jerosch-Herold; Elizabeth A Ivey; Julianna Keleti; Dong-Yun Kim; Paul Kolm; Raymond Y Kwong; Martin S Maron; Jeanette Schulz-Menger; Stefan Piechnik; Hugh Watkins; William S Weintraub; Pan Wu; Stefan Neubauer
Journal:  Am Heart J       Date:  2015-05-22       Impact factor: 4.749
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.